Diagnostic performance of the ClearLLab 10C B cell tube

Abstract

Introduction: Pre-analytical and analytical errors can threaten the reliability of flow cytometry (FC) results. A potential solution to some of these is the use of dry, premixed antibodies, such as the ClearLLab 10C system. The purpose of the present study was to compare the diagnostic performance of the ClearLLab 10C B cell tube with that of our standard laboratory practice.Methods: We compared the diagnoses made with the ClearLLab 10C B cell tube (experimental strategy) with those made with standard laboratory practice (standard strategy). Samples were selected aiming for representation of the full spectrum of B cell disorders, with an emphasis on mature B cell malignancies, as well as healthy controls.Results: We included 116 samples (34 normal controls, 4 acute lymphoblastic leukemias, 54 mature lymphoproliferative disorders in peripheral blood and bone marrow, 3 myelomas, 6 bone marrow samples with involvement by lymphoma and 1 with elevated hematogone count, 14 lymph node samples, 1 cerebrospinal fluid, and 1 pleural effusion). There were two diagnostic errors (1.7%). The agreement between the two strategies in the percentage of CD19 cells and fluorescence intensity of CD5, CD19, CD20, CD200, and CD10 was very good.Conclusions: In this study, the ClearLLab 10C B cell tube performed similarly to our standard laboratory practice to diagnose and classify mature B cell malignancies.

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia

“…The captured and amplified DNA was sequenced using NextSeq550 platform (Illumina ® ). The results were analyzed using DataGenomics platform as described elsewhere [37][38][39].…”

Issue Highlights—July 2021

“…Other multicolor antibody panels described and evaluated in this issue are a 10-color screening panel for B-cell neoplasia (Espasa et al, 2021) that includes CD200 (Sorigue et al, 2020), and a 10-color panel for MRD assessment in T-lymphoblastic leukemia (Tembhare et al, 2021). The former panel (Espasa et al, 2021), which makes use of dry reagents, has also been evaluated in a multicenter study recently reported in the journal (Hedley et al, 2021).…”

“…Gupta and colleagues, also in this issue (Gupta et al, 2021), illustrate the use of another multiparametric data visualization method, the radar plot (Jafari et al, 2018; Violidaki et al, 2020), to facilitate distinction between acute promyelocytic leukemia with PML‐RARA and AML with NPM1 mutation, whose phenotypes may overlap (Zhou et al, 2019). Other multicolor antibody panels described and evaluated in this issue are a 10‐color screening panel for B‐cell neoplasia (Espasa et al, 2021) that includes CD200 (Sorigue et al, 2020), and a 10‐color panel for MRD assessment in T‐lymphoblastic leukemia (Tembhare et al, 2021). The former panel (Espasa et al, 2021), which makes use of dry reagents, has also been evaluated in a multicenter study recently reported in the journal (Hedley et al, 2021).…”